Smith & Nephew plc · LSE:SN.

Smith & Nephew — 2006 American Academy of Orthopaedic Surgeons (AAOS) Analyst Meeting

59 slides from Smith & Nephew's conference presentation, Mar 22, 2006

  1. Slide 1: 2006 American Academy of Orthopaedic Surgeons

    2006 American Academy of Orthopaedic Surgeons Welcome to the Smith & Nephew Analyst Meeting March 22 2006

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and operating margins discussed under "Outlook" are forward- looking s

  3. Slide 3: Today's agenda

    Today’s agenda • Introduction Chris O’Donnell • Our businesses David Illingworth – Endoscopy Review David Illingworth – Hip arthroscopy Dr Marc Philippon • Orthopaedic Trauma & Clinical Therapies Mark Augusti • Orthopaedic Reconstruction Scott Flora • Wrap up David Illingworth • Q&A All ™ Trademark

  4. Slide 4: Strategic initiatives for growth

    Strategic initiatives for growth Improve market and customer focus • Separate segment and identity for Reconstruction/Trauma • Revised business focus for Advanced Wound Management Provide additional management capacity • CEO to focus strategy/business development • COO to drive business growth Impro

  5. Slide 5: Orthopaedic Academy – today's backcloth

    Orthopaedic Academy – today’s backcloth • 2006 Estimated market growth rates Reconstruction c. 10% Trauma c. 11% Arthroscopy c. 8% • S&N pricing - positive outcome plus health economics drive neutral to slightly positive pricing • S&N mix - new product slate improves mix • Strategy - continue to out

  6. Slide 6: Our businesses

    Our businesses David Illingworth Chief Operating Officer

  7. Slide 7: New business structure for 2006

    New business structure for 2006 Market opportunity Circa $17 billion 2005 Revenue $2½ billion Growth 11% • Four business segments Endoscopy Orthopaedic $606m – Market and business focus Reconstruction $829m – Structured for growth Advanced – Target markets Trauma Wound & Clinical – Common science ba

  8. Slide 8: Endoscopy

    Endoscopy David Illingworth Chief Operating Officer

  9. Slide 9: Endoscopy market drivers

    Endoscopy market drivers Longer living, more active No 1 in arthroscopy - worldwide population Others Patient preference for endoscopic ArthroCare 5% procedures 6% Smith & Nephew 29% Improving payor outlook driven by Stryker supporting clinical outcomes 12 % Increase in surgeon training Ambulatory s

  10. Slide 10: Key strengths

    Key strengths Full line arthroscopy business Unmatched product portfolio/technical expertise Largest global selling resource - Procedure specific segmentation - Surgeon training Shaping and growing markets - Knee, shoulder, hip and spine

  11. Slide 11: Growth drivers

    Growth drivers Digital OR and visualization systems Refocused access, mechanical and RF resection Hip arthroscopy Conversion of further shoulder procedures to arthroscopic Sales force and surgeon education

  12. Slide 12: What's new at AAOS? Key products

    What’s new at AAOS? Key products Knee CALAXO™ Osteoconductive Interference Screw Promotes bone regrowth in ONE year Resorbable ACL fixation screw Access DYONICS™ 25 Fluid Management System Ease of use Consistent performance Variety of tubing options Everyday, endoscopic procedures Digital OR develop

  13. Slide 13: What's new at AAOS? Key new products

    What’s new at AAOS? Key new products Hip Arthroscopy Hip Positioning System Advanced simplicity for Hip arthro procedures Attaches to standard OR tables CLEAR-TRAC™ COMPLETE Disposable Hip Cannula System Threaded for easy insertion, retention Allows surgeon to view suture and instruments BIORAPTOR™

  14. Slide 14: New Frontiers in Hip Arthroscopy

    New Frontiers in Hip Arthroscopy Marc J. Philippon MD Steadman-Hawkins Clinic Steadman-Hawkins Research Foundation Vail, CO

  15. Slide 15: Hip Arthroscopy: Historical Perspective

    Hip Arthroscopy Historical Perspective • Takagi (1939) reported 4 cases • 2 Charcot joints • 1 TB • 1 septic arthritis

  16. Slide 16: Hip Arthroscopy: Personal Experience

    Hip Arthroscopy Personal Experience • ~ 3000 hip arthroscopies (1995-2006) • ~ 1/3 in high school, amateur, and professional athletes • Hip arthroscopy has evolved over this • time period from treating isolated soft • tissue injuries (labral, chondral, • capsular) to treating associated • bony patho

  17. Slide 17: Intra-articular Hip Pathologies Commonly Treated with Hip Arthroscopy

    • Intra-articular Hip Pathologies Commonly Treated with Hip Arthroscopy z Acetabular Labral Tears

  18. Slide 18: Intra-articular Hip Pathologies Commonly Treated with Hip Arthroscopy

    Intra-articular Hip Pathologies Commonly Treated with Hip Arthroscopy z Acetabular Labral Tears z Femoroacetabular Impingement NORMAL CAM PINCER MIXED Lavigne et al. CORR 2004

  19. Slide 19: Femoroacetabular Impingement

    Femoroacetabular Impingement • Results from a bony abnormality • of either the proximal femur • (cam) or acetabulum (pincer) • Repetitive bony abutment damages the articular cartilage and labrum • Patients complain of pain with deep flexion and commonly have decreased flexion and internal rotation

  20. Slide 20: Intra-articular Hip Pathologies Commonly Treated with Hip Arthroscopy

    • Intra-articular Hip Pathologies Commonly Treated with Hip Arthroscopy z Acetabular Labral Tears z Femoroacetabular Impingement z Chondral defects Acetabulum Femoral Head

  21. Slide 21: Hip Arthroscopy: Modified Supine Approach

    Hip Arthroscopy: Modified Supine Approach

  22. Slide 22: Portals

    PORTALS

  23. Slide 23: Treatment of Labral Tears

    Treatment of Labral Tears • Historically, acetabular labral tears were debrided or resected • Recent evidence has shown: z Repair is technically possible z Healing is present 8-12 weeks after repair z Clinical outcomes are significantly better in re-fixation patients when compared to resection follo

  24. Slide 24: When to repair?

    When to repair? • Important pre-operative considerations: z Patient activity level z Location of tear z Morphology of tear z Size of tear z Associated pathologies

  25. Slide 25: 31 y/o professional hockey player with L hip pain

    31 y/o professional Labral pathology Hockey player c/o L hip pain

  26. Slide 26: 31 y/o professional hockey player with L hip pain

    31 y/o professional Labral pathology Hockey player c/o L hip pain Suture anchor repair x2

  27. Slide 27: 31 y/o professional hockey player with L hip pain

    31 y/o professional Labral pathology Hockey player c/o L hip pain Repaired labrum

  28. Slide 28: 2nd Look Labral Repair

    2nd Look Labral Repair

  29. Slide 29: Personal Experience

    Personal Experience September 2002 to March 2006 z ~ 900 labral repairs performed z Technique has evolved z No complications specifically related to the labral repair technique z Now most commonly performed in conjunction with treatment of femoroacetabular impingement

  30. Slide 30: Treatment of FAI

    Treatment of FAI • Goal of arthroscopy is to remove the bony prominence from the femoral neck (osteoplasty) or acetabulum (rim trimming) to create joint clearance during movement • Labrum is re-attached to acetabular rim if detached during arthroscopy

  31. Slide 31: Outcomes of FAI Treatment

    Outcomes of FAI Treatment • First surgical technique described to treat FAI involved an open surgical hip dislocation • Beck et al. reported 68% good to excellent results with this technique • This invasive technique may not be optimal for highly active patients

  32. Slide 32: Outcomes of FAI Treatment

    Outcomes of FAI Treatment • Philippon et al. • (AAOS 2006, AOSSM Specialty Day 2006) z Outcome of arthroscopic technique in professional athletes z Prior to arthroscopy, the athletes complained of pain and were unable to participate in their sport z 93% of the athletes returned to professional sport

  33. Slide 33: Treatment of Chondral Defects

    Treatment of Chondral Defects • Arthroscopic chondroplasty • Arthroscopic microfracture z Bone marrow stimulating technique for full- thickness articular cartilage defects z Knee studies have shown fibrocartilaginous healing and good clinical outcomes

  34. Slide 34: 2nd Look Microfracture

    2nd Look Microfracture Acetabular Chondral Defects Primary Arthroscopy • 4 professional athletes • Initial defect = 200 mm2 • Average time to 2nd look = 65 weeks Second-Look • % fill = 98% (95-100%) • 3 athletes returned to play Philippon et al. AANA 2006, Miami, FL

  35. Slide 35: The Future of Hip Arthroscopy

    The Future of Hip Arthroscopy • Diagnostic skills and arthroscopic techniques have been evolving over the last 10 years to treat a variety of intra- articular hip pathologies • Recent focus has been on FAI as a major source of hip pain, soft tissue injury, and joint degeneration • Early outcome stud

  36. Slide 36: Thank you!

  37. Slide 37: Orthopaedic Trauma & Clinical Therapies

    Orthopaedic Trauma & Clinical Therapies Mark Augusti President

  38. Slide 38: Trauma & Clinical Therapies 2005 global market

    Trauma & Clinical Therapies 2005 global market $4 Billion • Growth up 12-13% Ex Fix • Clinical Therapies growth up 13% 8-9% JFT Drivers 14% In Fix • Population aging Lg Bon 66% e Stim • Active lifestyles 7% • Technologies • Surgeon specialization

  39. Slide 39: Trauma & Clinical Therapies 2005 performance

    Trauma & Clinical Therapies 2005 performance • Strong Revenues 20% Growth – Trauma Implants 14% Growth, (21% US) – Long Bone Stimulation 39% Growth 5 Points of – Joint Fluid Therapy 37% Growth Market Share • Sales Force Expansion – Trauma 180 US – Clinical Therapies 200 US • Expanded Product Portfol

  40. Slide 40: Trauma & Clinical Therapies customer focus

    Trauma & Clinical Therapies customer focus • Continued increase in Trauma and Clinical Therapies sales representatives Continued Significant • Dedicated Trauma Sales Industry Support Management implemented • Increased focus on Medical Education - MOBILAB™ • Focused Sales Channel in Europe & Japan •

  41. Slide 41: Trauma & Clinical Therapies introducing TRIGEN INTERTAN Nail

    Trauma & Clinical Therapies introducing TRIGEN™ INTERTAN Nail • $300+m high growth market • Recognition that as Dr. Toney Russell says, “the gold standard for outcomes has room for improvement.” – Only 25% of hip fracture patients will make a full recovery – 40% will require nursing home care – 50%

  42. Slide 42: Trauma & Clinical Therapies New products

    Trauma & Clinical Therapies New products • Additional minimally invasive PERI-LOC™ instrumentation • PERI-LOC Plating System for the Upper Extremity • New cannulated Screws • TRIGEN™ Nail innovations - INTERTAN • EXOGEN 4000+™ System* • SUPARTZ™ Joint Fluid Therapy 3-4-5 Labeling * Not FDA approved

  43. Slide 43: Impacting lives: custom PERI-LOC plate makes surgery possible

    Impacting lives: custom PERI-LOC™ plate makes surgery possible • Dr. Cynthia Kelly, Denver Colorado • Patient with malignant bone tumor • Express Implants Group creates custom plate • Procedure called for Allograft and a plate • “The plate fit perfectly – like a dream come true.” • Successful outcom

  44. Slide 44: Trauma & Clinical Therapies summary

    Trauma & Clinical Therapies summary • Strong industry fundamentals • Well positioned & driven – Sales force specialization – Focused structure – Superior products and technology

  45. Slide 45: Orthopaedic Reconstruction

    Orthopaedic Reconstruction Scott Flora President

  46. Slide 46: Reconstruction 2005 global market

    Reconstruction 2005 global market Market = $9billion, Up 11% CC Market drivers • Demographics - Doubles age +55 by 2020 • Obesity Hips • Active people Knees 46% 48% • Treatment alternatives/new technology - Consumer awareness • Price/Mix varies by - Geography Cement Shoulders - Procedure type 4% 2%

  47. Slide 47: Reconstruction 2005 performance

    Reconstruction 2005 performance Driven by advanced technology – OXINIUM™ technology GENESIS™ II OXINIUM™ Knee – MIS hip and knees Sales force – Growth – Improved focus BIRMINGHAM HIP™ Resurfacing momentum Market growth: 11% Smith & Nephew: WW Knee growth: 15% US Knee growth: 15% WW Hip growth: 13% B

  48. Slide 48: Reconstruction What's next

    Reconstruction What’s next • Specialized sales and service for customers on a global basis • New products • Leverage unique portfolio Minimally Invasive Hip Instruments EMPERION™ Modular Hip ANTHOLOGY™ Flat Hip System

  49. Slide 49: Reconstruction Global sales and service coverage

    Reconstruction Global sales and service coverage US: Dedicated sales structure – Specialized services – MOBILAB™/training Europe: Steve Couldwell – Dedicated sales structure – Metal-on-metal center of excellence – Training Japan: Shuichi Matsunaga – Leading Medical – Dedicated sales team Specialized

  50. Slide 50: Reconstruction Continued out-performance

    Reconstruction Continued out-performance New Products • LEGION™ Revision Knee System • JOURNEY™ Anatomical Knee System • ANTHOLOGY™ Flat Hip System • EMPERION™ Modular Hip • BIRMINGHAM HIP™ Resurfacing (Subject to FDA approval for use in U.S.)

  51. Slide 51: Reconstruction LEGION Revision Knee

    Reconstruction LEGION™ Revision Knee • First revision entry for Smith & Nephew in fast growing revision market – Innovative design provides unprecedented access to competitive accounts. • Designed by revision surgeons for revision surgery • Meets surgeon needs – Reduced operating time – Revision spe

  52. Slide 52: Reconstruction Journey Anatomical Knee

    Reconstruction Journey™ Anatomical Knee • First to restore normal knee function • Design based on natural anatomy - Bi-Cruciate Stabilized - “Gender Optimized” Sizing • Innovative, Proprietary design tools – Unrivaled Biomechanical Analysis – Design goal of providing Normal Kinetics/Kinematics JOURN

  53. Slide 53: Reconstruction BIRMINGHAM HIP Resurfacing

    Reconstruction BIRMINGHAM HIP™ Resurfacing • Alternative for the young, active patient • Patient demand • Proven low wear, range of motion, highly stable • #1 Hip resurfacing in the world • 50,000 surgeries globally • FDA approval request filed BIRMINGHAM HIP™ Resurfacing Excellence driven by experi

  54. Slide 54: Reconstruction Unique bearing portfolio

    Reconstruction Unique bearing portfolio

  55. Slide 55: Reconstruction Summary

    Reconstruction Summary • Strong market fundamentals • Great products, unique technology • Sales force specialized • Momentum in 2006 and beyond JOURNEY™ Bi-Cruciate ANTHOLOGY™ Flat Hip Stem LEGION™ Revision Knee Stabilized Knee

  56. Slide 56: Wrap up

    Wrap up Dave Illingworth Chief Operating Officer

  57. Slide 57: Smith & Nephew strategy

    Smith & Nephew strategy • Exploit positive market dynamics • Build on technology leadership to expand markets • Organic growth – Innovative product pipeline – Sales force development • Pursue synergistic technology acquisitions • Build on Smith & Nephew brand Strategy continuing to drive growth and

  58. Slide 58: Smith & Nephew at AAOS

    Smith & Nephew at AAOS • Orthopaedic Reconstructive, Trauma & Clinical Therapies –Booth Number: 400 • Endoscopy –Booth Number: 616 • MOBILAB Mobile Training Center –Booth Number: 5247

  59. Slide 59: We are smith&nephew

    >KWe are smith&nephew

Smith & Nephew — 2006 American Academy of Orthopaedic Surgeons (AAOS) Analyst Meeting on 6ix